吉非替尼对比吉非替尼联合培美曲塞和卡铂化疗在EGFR突变肺癌中的研究
这项III期随机试验纳入350例EGFR敏感突变晚期非小细胞肺癌患者,比较吉非替尼单药与吉非替尼联合培美曲塞和卡铂化疗。联合组中位无进展生存期16个月显著长于单药组8个月,中位总生存期联合组未达到而单药组17个月,但联合组3级及以上毒性发生率51%高于单药组25%。
要点
- 联合化疗显著延长PFS(16 vs 8个月,HR 0.51)和OS(未达到 vs 17个月,HR 0.45)。
- 联合组3级及以上毒性发生率51%,显著高于单药组25%。
核心结论
- 在EGFR敏感突变晚期NSCLC患者中,吉非替尼联合培美曲塞和卡铂化疗较吉非替尼单药显著延长PFS和OS,但增加毒性。
研究设计与样本
- III期随机试验,纳入350例EGFR敏感突变晚期NSCLC且体能状态0-2、计划一线姑息治疗的患者,1:1随机分配至吉非替尼250mg口服每日一次(n=176)或吉非替尼250mg口服每日一次联合培美曲塞500mg/m2和卡铂AUC 5静脉每3周一次共4周期后培美曲塞维持(n=174)。
临床怎么用
- 对于EGFR敏感突变晚期NSCLC且体能状态0-2、适合化疗的患者,可考虑吉非替尼联合培美曲塞和卡铂作为一线治疗选择,但需密切监测毒性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Standard first-line therapy for EGFR-mutant advanced non-small-cell lung cancer (NSCLC) is an epidermal growth factor receptor (EGFR)-directed oral tyrosine kinase inhibitor. Adding pemetrexed and carboplatin chemotherapy to an oral tyrosine kinase inhibitor may improve outcomes. PATIENTS AND METHODS: This was a phase III randomized trial in patients with advanced NSCLC harboring an EGFR-sensitizing mutation and a performance status of 0 to 2 who were planned to receive first-line palliative therapy. Random assignment was 1:1 to gefitinib 250 mg orally per day (Gef) or gefitinib 250 mg orally per day plus pemetrexed 500 mg/m2 and carboplatin area under curve 5 intravenously every 3 weeks for four cycles, followed by maintenance pemetrexed (gefitinib plus chemotherapy [Gef+C]). The primary end point was progression-free survival (PFS); secondary end points included overall survival (OS), response rate, and toxicity. RESULTS: Between 2016 and 2018, 350 patients were randomly assigned to Gef (n = 176) and Gef+C (n = 174). Twenty-one percent of patients had a performance status of 2, and 18% of patients had brain metastases. Median follow-up time was 17 months (range, 7 to 30 months). Radiologic response rates were 75% and 63% in the Gef+C and Gef arms, respectively (P = .01). Estimated median PFS was significantly longer with Gef+C than Gef (16 months [95% CI, 13.5 to 18.5 months] v 8 months [95% CI, 7.0 to 9.0 months], respectively; hazard ratio for disease progression or death, 0.51 [95% CI, 0.39 to 0.66]; P < .001). Estimated median OS was significantly longer with Gef+C than Gef (not reached v 17 months [95% CI, 13.5 to 20.5 months]; hazard ratio for death, 0.45 [95% CI, 0.31 to 0.65]; P < .001). Clinically relevant grade 3 or greater toxicities occurred in 51% and 25% of patients in the Gef+C and Gef arms, respectively (P < .001). CONCLUSION: Adding pemetrexed and carboplatin chemotherapy to gefitinib significantly prolonged PFS and OS but increased toxicity in patients with NSCLC.
引用
- Noronha V, Patil VM, Joshi A, et al. Gefitinib Versus Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in EGFR-Mutated Lung Cancer. J Clin Oncol. 2019. PMID: 31411950. doi:10.1200/JCO.19.01154
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。